Analyzing Dare Bioscience (NASDAQ:DARE) & Scilex (NASDAQ:SCLX)

Scilex (NASDAQ:SCLX) and Dare Bioscience (NASDAQ:DARE) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Institutional & Insider Ownership

69.7% of Scilex shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 4.5% of Scilex shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Scilex has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.

Profitability

This table compares Scilex and Dare Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scilex	-1,414.57%	N/A	-147.00%
Dare Bioscience	-803.80%	-748.30%	-38.75%

Analyst Recommendations

This is a summary of current recommendations and price targets for Scilex and Dare Bioscience, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scilex	1	0	0	0	1.00
Dare Bioscience	1	0	3	0	2.50

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 1,208.90%. Given Dare Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Dare Bioscience is more favorable than Scilex.

Earnings and Valuation

This table compares Scilex and Dare Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scilex	$30.25 million	1.56	-$358.73 million	($49.70)	-0.11
Dare Bioscience	$1.03 million	11.34	-$13.40 million	($0.70)	-1.09

Dare Bioscience has lower revenue, but higher earnings than Scilex. Dare Bioscience is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Summary

Dare Bioscience beats Scilex on 8 of the 14 factors compared between the two stocks.

About Scilex

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.